StreetAlpha.app
Home › Stocks › QNRX

Quoin Pharmaceuticals Ltd. (QNRX)

$3.48
▼ −2.25%
LAST CLOSE · NOV 17

Quoin Pharmaceuticals develops topical drug candidates for rare genetic skin diseases, led by a lotion for Netherton Syndrome. It last closed at $3.48 on Nov 17, down 2.25% on the day. The average 12-month price target from 3 analysts is $17.33 (+398.1% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is QNRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$19.6M
Valuation
Market cap
$244.6M
70.3M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.1M
At Sep 30
Shareholder equity
$28.7M
Shares outstanding
70.3M
At Aug 12
ExchangeNasdaq
Financials history
FY2021: −$21.5M−$21.5MFY2021FY2022: −$9.4M−$9.4MFY2022FY2023: −$8.7M−$8.7MFY2023FY2024: −$9.0M−$9.0MFY2024FY2025: −$15.8M−$15.8MFY2025

From QNRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 6
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on QNRX in the past 90 days
Average 12-month target
$17.33
▲ 398.1% upside

Based on 3 analysts who set a price target on QNRX in the past 90 days. The average target is $17.33, with a high of $20.00 and a low of $14.00, compared with the last close of $3.48.

Low $14.00Avg $17.33High $20.00
Blue marker: last close $3.48
Highest target$20.00
Average target$17.33
Lowest target$14.00
Latest rating changes
Canaccord GenuityInitiated
Oct 19Buy$18
BTIGInitiated
Oct 12Buy$14
Lake StreetInitiated
Sep 23Buy$20
LUCID CAPITAL MARKETSInitiated
May 4Buy$30
DateFirmActionRatingPrice target
Oct 19Canaccord GenuityInitiatedBuy$18
Oct 12BTIGInitiatedBuy$14
Sep 23Lake StreetInitiatedBuy$20
May 4LUCID CAPITAL MARKETSInitiatedBuy$30
Loading…

Technical Analysis

QNRX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 13% below its 20 day and 39% below its 50 day average. It is 64% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the swing low (Nov 6) at $3.45, and the nearest resistance the Pivot R1 at $3.64.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 9.5%/day
Key levels
$23.5052 week high+575.3%
$5.72200 day average+64.4%
$4.93100 day average+41.7%
$4.8550 day average+39.4%
$4.50Swing high (Jul 22)+29.3%
$3.9220 day average+12.6%
$3.64Pivot R1+4.6%
$3.48Last close
$3.45Swing low (Nov 6)−0.9%
$3.44Pivot−1.1%
$3.29Pivot S1−5.5%
$3.2552 week low−6.6%
Indicators
RSI (14)34.68Weak, oversold below 30Neutral
MACD-0.29Above its signal lineBullish
Stochastic15.8Near the bottom of its rangeOversold
ADX (14)22.5Weak trend
Williams %R-83.2Oversold below −80, overbought above −20Oversold
CCI (20)-180.2Oversold below −100, overbought above 100Oversold
Rate of change−11.9%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QNRX

What happened before

See how QNRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow QNRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How QNRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in QNRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

QNRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲20 buying vs 11 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +6
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2519+31.6%
In funds' top 1000–
Held by funds3.8%1.9%+2.0 pts
New / increased15 / 51 / 9+100.0%
Reduced / sold out2 / 93 / 3+83.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QNRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNRX is in one of them and how their past QNRX trades turned out.

QNRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QNRX in an article yet. Here's the latest on the wider market.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a specialty drug developer based in Ashburn, Virginia. It focuses on treatments for rare and orphan diseases that have few or no approved options. Its lead product candidate, QRX003, is a topical lotion in clinical testing for Netherton Syndrome, a rare genetic skin disease, and it is also being studied for other rare skin conditions. The company plans to sell its products to patients and healthcare providers in the United States, Europe and Japan, and works with distribution partners in other countries. It has not yet commercialized any products.

Headquarters
Ashburn, VA